HA
CELG

Harfst & Associates’s Celgene Corp CELG Stock Holding History

Harfst & Associates’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-24
Closed -$3K – 241
2017
Q2 		$3K Hold
24
– – ﹤0.01% 223
2017
Q1 		$2K Buy
+24
New +$2.87K ﹤0.01% 279
2016
Q1 		– Sell
-24
Closed -$2K – 294
2015
Q4 		$2K Hold
24
– – ﹤0.01% 281
2015
Q3 		$3K Hold
24
– – ﹤0.01% 265
2015
Q2 		$3K Buy
+24
New +$2.74K ﹤0.01% 316

Other funds holding CELG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Harfst & Associates's CELG Position: Q3 2017 in Review

Harfst & Associates sold out of Celgene Corp (CELG) in Q3 2017, closing a stake of 24 shares — an estimated $3K sold.

Harfst & Associates first reported a position in CELG in Q2 2015 and held it in 5 quarters. The position peaked at $3K in Q2 2017. 1,484 funds tracked by Wall St. Rank hold CELG as of Q3 2017.

  • Harfst & Associates reported no remaining Celgene Corp position as of Q3 2017 after selling out during the quarter.
  • Harfst & Associates sold 24 Celgene Corp shares in Q3 2017, an estimated $3K.
  • Harfst & Associates first reported a position in Celgene Corp in Q2 2015 and held it in 5 quarters.
  • Harfst & Associates's Celgene Corp position peaked at $3K in Q2 2017.
  • 1,484 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2017.

Based on Harfst & Associates's 13F filing for Q3 2017, filed 7 Nov 2017.